Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 37.64% is 38% above its 4-year average of 27.23%, near the low end of its 4-year range (0.00%–40200.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 11.64% above its 12-month average of 33.72%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 37.64%.
DEBT TO ASSETS RATIO
37.64%
DEBT TO ASSETS RATIO AVG TTM
33.72%
DEBT TO ASSETS RATIO AVG 3Y
26.32%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+11.64%
CURRENT VS 3Y AVG
+43.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 575 covered companies
CURRENT VS SECTOR MEDIAN
+37544.33%
vs the sector median at left
CDT Equity Inc.
Market Cap
$667296.00
Debt to Assets Ratio
37.64%
TTM Avg
33.72%
3Y Avg
26.32%
5Y Avg
N/A
Market Cap
$564917.00
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833048.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$874595.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$883067.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.08M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CDT Equity Inc. (CDT) | $667296.00 | 37.64% | 33.72% | 26.32% | N/A |
| HCW Biologics Inc. (HCWB)vs › | $564917.00 | 0.25% | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $833048.00 | 0.01% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $874595.00 | 0.00% | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $883067.00 | 0.00% | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | 0.01% | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | 0.00% | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | 0.11% | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | 0.10% | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.19M | 0.47% | N/A | N/A | N/A |
Debt/Assets
37.6%
Debt/Equity
0.95
Current Ratio
2.14
Interest Coverage
-115.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 37.64% |
| 2026-03-29 | 39.03% |
| 2025-12-31 | 36.28% |
| 2025-09-28 | 21.92% |
| 2025-06-29 | 25.86% |
| 2025-03-30 | 39.16% |
| 2024-12-31 | 177.84% |
| 2024-09-29 | 89.07% |
| 2024-06-30 | 38.37% |
| 2024-03-31 | 26.34% |
| 2023-12-31 | 13.64% |
| 2023-09-30 | 8.16% |
| 2023-06-30 | 3.17% |
| 2023-03-31 | 1.25% |
| 2022-12-31 | 40200.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 83.08% |
